New study aims to uncover hidden health risks in 9/11 heroes
NCT ID NCT05216133
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 200 male FDNY rescue workers who were exposed to dust and toxins after the World Trade Center attacks. Many developed acid reflux, which can lead to Barrett's esophagus and even cancer. Researchers will use simple, noninvasive tests like saliva samples and questionnaires to find better ways to detect and understand these conditions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2023
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Male FDNY rescue and recovery workers between the ages of 37 and 90.
- Ages
-
37 to 90 years
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age 37-90 2. FDNY rescue and recovery worker. 3. Male\* 4. Documented WTC exposure. 5. Consented/Enrolled in the FDNY WTC Health Program 6. Subjects are willing and able to consent for themselves to study enrollment 7. Subjects are willing and able to participate in study procedures 8. Are able to perform their activities of daily living independently 9. Are either light duty or retired FDNY Firefighters 10. Spirometry available within the last 24 months, and at a post-9/11 visit. 11. Have means to accommodate transportation to/from in-person visit Are able to attend a single visit at the CTSI (462 1st Avenue, C \& D 4th Floor) 12. Pre-9/11 spirometry with FEV1%predicted ≥LLN and if not available 1st -post 9/11 spirometry with an FEV1 \>80% predicted. 13. Exposure at the WTC-site within 2 weeks of the 9/11/2001 14. Entered WTC-HP before the site closure on 7/24/2002. 15. Serum from their first post 9/11 WTC-HP visit is available in the FDNY WTC biorepository and may be assayed 16. Are not currently being treated for malignancy 17. Subjects will either need to be defined as having WTC-AHR, WTC-GERD, WTC-BE or be designated controls as per the following additional inclusion criteria are specific to the WTC-aerodigestive disease that the subjects have 18. AHR--A positive methacholine (PC20\<16) and/or positive bronchodilator response (ATS/ERS guidelines: improvement of FEV1 by 12% and at least 200mL) at least once post-9/11.\[95, 96\]No recorded positive AHR testing prior to 9/11 19. GERD Inclusion Criteria * Erosive esophagitis LA grade C or D (as described on endoscopy), OR * Stricture or Barrett's esophagus on endoscopy, OR * Esophageal acid exposure time \>6% on a pH or pH impedance study 19\. BE Inclusion Criteria * Columnar epithelium lining ≥1 cm of the distal esophagus. AND * Histologic examination of biopsy specimens from that columnar epithelium must reveal intestinal metaplasia characterized with goblet cells. Exclusion Criteria: 1. Unwilling to complete an informed consent. 2. Not enrolled in the WTC-HP 3. Do not meet eligibility criteria for AIM 1 or did not have serum available in the biorepository from the first post 9/11 WTC-HP visit. 4. Have pre-existing and documented conditions or concurrent diagnoses, including (and not necessarily limited to) active cancer, severe heart disease, significant cognitive impairment, eating disorders, significant psychiatric illness, end-stage COPD, severe pulmonary hypertension, or organ transplant. 5. High dose steroid (\>20mg prednisone or equivalent) or other hormonal treatments/chemotherapy use in the last month, including testosterone supplementation. 6. Life-expectancy \< 6 months 7. Female\*
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Airway disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
NYU Clinical & Translational Science Institute Clinical Research Center (CTSI CRC)
New York, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- What do patients really want when facing oesophageal cancer surgery?
- Can a radiofrequency zap calm stubborn heartburn?
- Can a Pre-Surgery checklist predict who will still have reflux after fundoplication?
- Could a gentler breath test replace the harsh blow for COPD diagnosis?
- Can thread acupuncture boost GERD relief beyond standard pills?
- New acid blocker may offer stronger reflux control for Barrett's esophagus